Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) is expected to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.11) per share and revenue of $52.25 million for the quarter.
Vanda Pharmaceuticals Price Performance
Shares of Vanda Pharmaceuticals stock opened at $4.69 on Friday. The business has a fifty day simple moving average of $4.66 and a two-hundred day simple moving average of $4.92. Vanda Pharmaceuticals has a 1 year low of $3.61 and a 1 year high of $6.75. The company has a market capitalization of $273.47 million, a price-to-earnings ratio of -16.75 and a beta of 0.74.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a report on Wednesday. They set a “hold” rating for the company. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday.
Insider Transactions at Vanda Pharmaceuticals
In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 8.90% of the stock is owned by company insiders.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Read More
- Five stocks we like better than Vanda Pharmaceuticals
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- Stock Market Upgrades: What Are They?
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
